Review



p ask1  (Bioss)


Bioz Verified Symbol Bioss is a verified supplier
Bioz Manufacturer Symbol Bioss manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Bioss p ask1
    Mcl-1shRNA combined with BCG vaccine may promote the apoptosis of mouse bladder cancer MB49 cells by activating the <t>ASK1/MKK7/JNK</t> signaling pathway. (A) Apoptosis of MB49 cells in different groups of Hoechst (scale: 50 μm). (B) Hoechst statistical analysis of apoptosis of MB49 cells in different groups. (C , D) Flow cytometry was used to detect the apoptosis of MB49 cells in different groups and make statistics. (E) Expression of <t>P-ASK1,</t> ASK1, P-MKK7, MKK7, P-JNK, JNK, P-cJUN, cJUN and CX43 in MB49 cells. (F) P-ASK1, ASK1, P-MKK7, MKK7, P-JNK, JNK, P-cJUN, cJUN, and CX43 protein expression analysis. * P < 0.05, ** P < 0.01, *** P < 0.001 compared with M0 + BCG-MB49 group; ## P < 0.01, ### P < 0.001 compared with M0 + BCG + Mcl-1shRNA-MB49 group
    P Ask1, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p ask1/product/Bioss
    Average 94 stars, based on 2 article reviews
    p ask1 - by Bioz Stars, 2026-02
    94/100 stars

    Images

    1) Product Images from "Mcl-1 downregulation enhances BCG treatment efficacy in bladder cancer by promoting macrophage polarization"

    Article Title: Mcl-1 downregulation enhances BCG treatment efficacy in bladder cancer by promoting macrophage polarization

    Journal: Cancer Cell International

    doi: 10.1186/s12935-025-03676-3

    Mcl-1shRNA combined with BCG vaccine may promote the apoptosis of mouse bladder cancer MB49 cells by activating the ASK1/MKK7/JNK signaling pathway. (A) Apoptosis of MB49 cells in different groups of Hoechst (scale: 50 μm). (B) Hoechst statistical analysis of apoptosis of MB49 cells in different groups. (C , D) Flow cytometry was used to detect the apoptosis of MB49 cells in different groups and make statistics. (E) Expression of P-ASK1, ASK1, P-MKK7, MKK7, P-JNK, JNK, P-cJUN, cJUN and CX43 in MB49 cells. (F) P-ASK1, ASK1, P-MKK7, MKK7, P-JNK, JNK, P-cJUN, cJUN, and CX43 protein expression analysis. * P < 0.05, ** P < 0.01, *** P < 0.001 compared with M0 + BCG-MB49 group; ## P < 0.01, ### P < 0.001 compared with M0 + BCG + Mcl-1shRNA-MB49 group
    Figure Legend Snippet: Mcl-1shRNA combined with BCG vaccine may promote the apoptosis of mouse bladder cancer MB49 cells by activating the ASK1/MKK7/JNK signaling pathway. (A) Apoptosis of MB49 cells in different groups of Hoechst (scale: 50 μm). (B) Hoechst statistical analysis of apoptosis of MB49 cells in different groups. (C , D) Flow cytometry was used to detect the apoptosis of MB49 cells in different groups and make statistics. (E) Expression of P-ASK1, ASK1, P-MKK7, MKK7, P-JNK, JNK, P-cJUN, cJUN and CX43 in MB49 cells. (F) P-ASK1, ASK1, P-MKK7, MKK7, P-JNK, JNK, P-cJUN, cJUN, and CX43 protein expression analysis. * P < 0.05, ** P < 0.01, *** P < 0.001 compared with M0 + BCG-MB49 group; ## P < 0.01, ### P < 0.001 compared with M0 + BCG + Mcl-1shRNA-MB49 group

    Techniques Used: Flow Cytometry, Expressing

    Mcl-1shRNA combined with BCG vaccine may treat bladder cancer in rats by activating the ASK1/MKK7/JNK signaling pathway. (A) Immunofluorescence detection of ASK1 and P-ASK1 expression in bladder tissue of rats in each group (scale: 50 μm). (B) Immunofluorescence detection of MKK7 and P-MKK7 expression in bladder cancer tissues of rats in each group (scale: 50 μm). (C) Immunofluorescence detection of the expression of JNK and P-JNK in bladder cancer tissues of rats in each group (scale: 50 μm). (D) Immunofluorescence detection of cJUN and P-CJUN expression in bladder cancer tissues of rats in each group (scale: 50 μm)
    Figure Legend Snippet: Mcl-1shRNA combined with BCG vaccine may treat bladder cancer in rats by activating the ASK1/MKK7/JNK signaling pathway. (A) Immunofluorescence detection of ASK1 and P-ASK1 expression in bladder tissue of rats in each group (scale: 50 μm). (B) Immunofluorescence detection of MKK7 and P-MKK7 expression in bladder cancer tissues of rats in each group (scale: 50 μm). (C) Immunofluorescence detection of the expression of JNK and P-JNK in bladder cancer tissues of rats in each group (scale: 50 μm). (D) Immunofluorescence detection of cJUN and P-CJUN expression in bladder cancer tissues of rats in each group (scale: 50 μm)

    Techniques Used: Immunofluorescence, Expressing

    Mcl-1 shRNA combined with BCG vaccine may promote the apoptosis of bladder cancer cells by activating the ASK1/MKK7/JNK signaling pathway and enhance the efficacy of treating bladder cancer in rats. (A) Tunel staining of rat bladder tissue in each group (scale: 100 μm). (B) Protein band diagrams of Bax and Bcl-2 in bladder cancer tissues of rats in each group. (C , D) Protein expression analysis of CyclinD1 and PCNA in bladder cancer tissues of rats in each group. (E) Immunohistochemistry detects the expression of P-JNK, P-cJUN, and CX43 in the bladder tissue of rats in each group (scale: 50 μm). (F) cJUN, P-CJUN and CX43 protein band diagrams in bladder cancer tissues of rats in each group. (G) Protein band diagrams of P-JNK and JNK in bladder cancer tissues of rats in each group. (H) Analysis of cJUN and P-CJUN protein expression in bladder cancer tissues of rats in each group. (I) Analysis of JNK and P-JNK protein expression in bladder cancer tissues of rats in each group. (J) CX43 protein expression analysis in bladder cancer tissues of rats in each group. * P < 0.05, ** P < 0.01, *** P < 0.001 compared with Sham group; # P < 0.05, ## P < 0.01, ### P < 0.001 compared with BLCA group; & P < 0.05, && P < 0.01, &&& P < 0.001 compared with BCG group; $ P < 0.05, $$ P < 0.01 compared with BCG + Mcl-1shRNA group
    Figure Legend Snippet: Mcl-1 shRNA combined with BCG vaccine may promote the apoptosis of bladder cancer cells by activating the ASK1/MKK7/JNK signaling pathway and enhance the efficacy of treating bladder cancer in rats. (A) Tunel staining of rat bladder tissue in each group (scale: 100 μm). (B) Protein band diagrams of Bax and Bcl-2 in bladder cancer tissues of rats in each group. (C , D) Protein expression analysis of CyclinD1 and PCNA in bladder cancer tissues of rats in each group. (E) Immunohistochemistry detects the expression of P-JNK, P-cJUN, and CX43 in the bladder tissue of rats in each group (scale: 50 μm). (F) cJUN, P-CJUN and CX43 protein band diagrams in bladder cancer tissues of rats in each group. (G) Protein band diagrams of P-JNK and JNK in bladder cancer tissues of rats in each group. (H) Analysis of cJUN and P-CJUN protein expression in bladder cancer tissues of rats in each group. (I) Analysis of JNK and P-JNK protein expression in bladder cancer tissues of rats in each group. (J) CX43 protein expression analysis in bladder cancer tissues of rats in each group. * P < 0.05, ** P < 0.01, *** P < 0.001 compared with Sham group; # P < 0.05, ## P < 0.01, ### P < 0.001 compared with BLCA group; & P < 0.05, && P < 0.01, &&& P < 0.001 compared with BCG group; $ P < 0.05, $$ P < 0.01 compared with BCG + Mcl-1shRNA group

    Techniques Used: shRNA, TUNEL Assay, Staining, Expressing, Immunohistochemistry



    Similar Products

    p ask1  (Bioss)
    94
    Bioss p ask1
    Mcl-1shRNA combined with BCG vaccine may promote the apoptosis of mouse bladder cancer MB49 cells by activating the <t>ASK1/MKK7/JNK</t> signaling pathway. (A) Apoptosis of MB49 cells in different groups of Hoechst (scale: 50 μm). (B) Hoechst statistical analysis of apoptosis of MB49 cells in different groups. (C , D) Flow cytometry was used to detect the apoptosis of MB49 cells in different groups and make statistics. (E) Expression of <t>P-ASK1,</t> ASK1, P-MKK7, MKK7, P-JNK, JNK, P-cJUN, cJUN and CX43 in MB49 cells. (F) P-ASK1, ASK1, P-MKK7, MKK7, P-JNK, JNK, P-cJUN, cJUN, and CX43 protein expression analysis. * P < 0.05, ** P < 0.01, *** P < 0.001 compared with M0 + BCG-MB49 group; ## P < 0.01, ### P < 0.001 compared with M0 + BCG + Mcl-1shRNA-MB49 group
    P Ask1, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p ask1/product/Bioss
    Average 94 stars, based on 1 article reviews
    p ask1 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Mcl-1shRNA combined with BCG vaccine may promote the apoptosis of mouse bladder cancer MB49 cells by activating the ASK1/MKK7/JNK signaling pathway. (A) Apoptosis of MB49 cells in different groups of Hoechst (scale: 50 μm). (B) Hoechst statistical analysis of apoptosis of MB49 cells in different groups. (C , D) Flow cytometry was used to detect the apoptosis of MB49 cells in different groups and make statistics. (E) Expression of P-ASK1, ASK1, P-MKK7, MKK7, P-JNK, JNK, P-cJUN, cJUN and CX43 in MB49 cells. (F) P-ASK1, ASK1, P-MKK7, MKK7, P-JNK, JNK, P-cJUN, cJUN, and CX43 protein expression analysis. * P < 0.05, ** P < 0.01, *** P < 0.001 compared with M0 + BCG-MB49 group; ## P < 0.01, ### P < 0.001 compared with M0 + BCG + Mcl-1shRNA-MB49 group

    Journal: Cancer Cell International

    Article Title: Mcl-1 downregulation enhances BCG treatment efficacy in bladder cancer by promoting macrophage polarization

    doi: 10.1186/s12935-025-03676-3

    Figure Lengend Snippet: Mcl-1shRNA combined with BCG vaccine may promote the apoptosis of mouse bladder cancer MB49 cells by activating the ASK1/MKK7/JNK signaling pathway. (A) Apoptosis of MB49 cells in different groups of Hoechst (scale: 50 μm). (B) Hoechst statistical analysis of apoptosis of MB49 cells in different groups. (C , D) Flow cytometry was used to detect the apoptosis of MB49 cells in different groups and make statistics. (E) Expression of P-ASK1, ASK1, P-MKK7, MKK7, P-JNK, JNK, P-cJUN, cJUN and CX43 in MB49 cells. (F) P-ASK1, ASK1, P-MKK7, MKK7, P-JNK, JNK, P-cJUN, cJUN, and CX43 protein expression analysis. * P < 0.05, ** P < 0.01, *** P < 0.001 compared with M0 + BCG-MB49 group; ## P < 0.01, ### P < 0.001 compared with M0 + BCG + Mcl-1shRNA-MB49 group

    Article Snippet: Anti-JNK (1:5000, 66210-1-Ig), anti-ASK1 (1:3000, 67072-1-Ig), anti-CX43 (1:4000, 26980-1-AP) were purchased from Proteintech Biotechnology Co., LTD. (Wuhan, China).The following antibodies: Bax (1:1000, bs-4605R), Bcl-2 (1:1000, bsm-52304R), P-ASK1(1:3000, bs-3029R), MKK7 (1:1000, bs-1979R), P-MKK7 (1:300, bs-3277R), P-JNK (1:500, bs-1640R), cJUN (1:1000, bs-0670R), P-cJUN (1:1000, bsm-52141R), CyclinD1 (1:1000, bsm-52046R) and PCNA (1:1000, bsm-52347R), were obtained from Bioss Biotechnology Co., LTD. (Beijing, China).

    Techniques: Flow Cytometry, Expressing

    Mcl-1shRNA combined with BCG vaccine may treat bladder cancer in rats by activating the ASK1/MKK7/JNK signaling pathway. (A) Immunofluorescence detection of ASK1 and P-ASK1 expression in bladder tissue of rats in each group (scale: 50 μm). (B) Immunofluorescence detection of MKK7 and P-MKK7 expression in bladder cancer tissues of rats in each group (scale: 50 μm). (C) Immunofluorescence detection of the expression of JNK and P-JNK in bladder cancer tissues of rats in each group (scale: 50 μm). (D) Immunofluorescence detection of cJUN and P-CJUN expression in bladder cancer tissues of rats in each group (scale: 50 μm)

    Journal: Cancer Cell International

    Article Title: Mcl-1 downregulation enhances BCG treatment efficacy in bladder cancer by promoting macrophage polarization

    doi: 10.1186/s12935-025-03676-3

    Figure Lengend Snippet: Mcl-1shRNA combined with BCG vaccine may treat bladder cancer in rats by activating the ASK1/MKK7/JNK signaling pathway. (A) Immunofluorescence detection of ASK1 and P-ASK1 expression in bladder tissue of rats in each group (scale: 50 μm). (B) Immunofluorescence detection of MKK7 and P-MKK7 expression in bladder cancer tissues of rats in each group (scale: 50 μm). (C) Immunofluorescence detection of the expression of JNK and P-JNK in bladder cancer tissues of rats in each group (scale: 50 μm). (D) Immunofluorescence detection of cJUN and P-CJUN expression in bladder cancer tissues of rats in each group (scale: 50 μm)

    Article Snippet: Anti-JNK (1:5000, 66210-1-Ig), anti-ASK1 (1:3000, 67072-1-Ig), anti-CX43 (1:4000, 26980-1-AP) were purchased from Proteintech Biotechnology Co., LTD. (Wuhan, China).The following antibodies: Bax (1:1000, bs-4605R), Bcl-2 (1:1000, bsm-52304R), P-ASK1(1:3000, bs-3029R), MKK7 (1:1000, bs-1979R), P-MKK7 (1:300, bs-3277R), P-JNK (1:500, bs-1640R), cJUN (1:1000, bs-0670R), P-cJUN (1:1000, bsm-52141R), CyclinD1 (1:1000, bsm-52046R) and PCNA (1:1000, bsm-52347R), were obtained from Bioss Biotechnology Co., LTD. (Beijing, China).

    Techniques: Immunofluorescence, Expressing

    Mcl-1 shRNA combined with BCG vaccine may promote the apoptosis of bladder cancer cells by activating the ASK1/MKK7/JNK signaling pathway and enhance the efficacy of treating bladder cancer in rats. (A) Tunel staining of rat bladder tissue in each group (scale: 100 μm). (B) Protein band diagrams of Bax and Bcl-2 in bladder cancer tissues of rats in each group. (C , D) Protein expression analysis of CyclinD1 and PCNA in bladder cancer tissues of rats in each group. (E) Immunohistochemistry detects the expression of P-JNK, P-cJUN, and CX43 in the bladder tissue of rats in each group (scale: 50 μm). (F) cJUN, P-CJUN and CX43 protein band diagrams in bladder cancer tissues of rats in each group. (G) Protein band diagrams of P-JNK and JNK in bladder cancer tissues of rats in each group. (H) Analysis of cJUN and P-CJUN protein expression in bladder cancer tissues of rats in each group. (I) Analysis of JNK and P-JNK protein expression in bladder cancer tissues of rats in each group. (J) CX43 protein expression analysis in bladder cancer tissues of rats in each group. * P < 0.05, ** P < 0.01, *** P < 0.001 compared with Sham group; # P < 0.05, ## P < 0.01, ### P < 0.001 compared with BLCA group; & P < 0.05, && P < 0.01, &&& P < 0.001 compared with BCG group; $ P < 0.05, $$ P < 0.01 compared with BCG + Mcl-1shRNA group

    Journal: Cancer Cell International

    Article Title: Mcl-1 downregulation enhances BCG treatment efficacy in bladder cancer by promoting macrophage polarization

    doi: 10.1186/s12935-025-03676-3

    Figure Lengend Snippet: Mcl-1 shRNA combined with BCG vaccine may promote the apoptosis of bladder cancer cells by activating the ASK1/MKK7/JNK signaling pathway and enhance the efficacy of treating bladder cancer in rats. (A) Tunel staining of rat bladder tissue in each group (scale: 100 μm). (B) Protein band diagrams of Bax and Bcl-2 in bladder cancer tissues of rats in each group. (C , D) Protein expression analysis of CyclinD1 and PCNA in bladder cancer tissues of rats in each group. (E) Immunohistochemistry detects the expression of P-JNK, P-cJUN, and CX43 in the bladder tissue of rats in each group (scale: 50 μm). (F) cJUN, P-CJUN and CX43 protein band diagrams in bladder cancer tissues of rats in each group. (G) Protein band diagrams of P-JNK and JNK in bladder cancer tissues of rats in each group. (H) Analysis of cJUN and P-CJUN protein expression in bladder cancer tissues of rats in each group. (I) Analysis of JNK and P-JNK protein expression in bladder cancer tissues of rats in each group. (J) CX43 protein expression analysis in bladder cancer tissues of rats in each group. * P < 0.05, ** P < 0.01, *** P < 0.001 compared with Sham group; # P < 0.05, ## P < 0.01, ### P < 0.001 compared with BLCA group; & P < 0.05, && P < 0.01, &&& P < 0.001 compared with BCG group; $ P < 0.05, $$ P < 0.01 compared with BCG + Mcl-1shRNA group

    Article Snippet: Anti-JNK (1:5000, 66210-1-Ig), anti-ASK1 (1:3000, 67072-1-Ig), anti-CX43 (1:4000, 26980-1-AP) were purchased from Proteintech Biotechnology Co., LTD. (Wuhan, China).The following antibodies: Bax (1:1000, bs-4605R), Bcl-2 (1:1000, bsm-52304R), P-ASK1(1:3000, bs-3029R), MKK7 (1:1000, bs-1979R), P-MKK7 (1:300, bs-3277R), P-JNK (1:500, bs-1640R), cJUN (1:1000, bs-0670R), P-cJUN (1:1000, bsm-52141R), CyclinD1 (1:1000, bsm-52046R) and PCNA (1:1000, bsm-52347R), were obtained from Bioss Biotechnology Co., LTD. (Beijing, China).

    Techniques: shRNA, TUNEL Assay, Staining, Expressing, Immunohistochemistry